NeurologyLive® Friday 5 — May 3, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 3, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Special Episode: FDA Approves Diazepam Buccal Film for Pediatric Seizures

This episode, "FDA Approves Diazepam Buccal Film for Pediatric Seizures," features an exclusive interview with Michael Rogawski, MD, PhD, an epilepsy expert, who sat down to discuss the significance of the FDA approval of diazepam buccal film (Libervant; Aquestive Therapeutics) as a new treatment for pediatric patients with intermittent, stereotypic episodes of seizure activity.

Special Episode: FDA Approves Diazepam Buccal Film for Pediatric Seizures

2: AI-Powered Neurotech Could Revolutionize Dementia Care and Unlock Communications

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how emerging neurotechnology, such as mobile EEG devices paired with customized AI and machine learning models, is poised to transform the fight against dementia.

AI-Powered Neurotech Could Revolutionize Dementia Care and Unlock Communications

3: Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care

Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population.

Applying the Innovation Biodesign Framework to Promote Equity and Green Activity in Dementia Care

4: NeuroVoices: Eoin P. Flanagan, MB, BCh, on the Potential Significance of Spinal Fluid Testing for MOGAD Diagnosis

The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated disease.

NeuroVoices: Eoin P. Flanagan, MB, BCh, on the Potential Significance of Spinal Fluid Testing for MOGAD Diagnosis

5: Leveraging Artificial Intelligence to Redefine Clinical Efficacy and Empower Neurologists: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology. [WATCH TIME: 4 minutes]

 Leveraging Artificial Intelligence to Redefine Clinical Efficacy and Empower Neurologists: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN
Related Videos
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.